Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL
The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
Source: OncLive